95 results about "Retinopathy" patented technology

The present invention provides methods of treating ocular disorders with modulators of the WNT signaling pathway. In particular the ocular disorders are retinopathies. Also provided are methods of dosing and pharmaceutical compositions.

Disclosed herein are embodiments of a polymer-based implant and methods of making and using the same. The polymer-based implant comprises a polymer component and a therapeutic agent. In some embodiments, the polymer-based implant can be used to treat and / or prevent retinal diseases and / or retinopathies. The polymer-based implant exhibits physical properties that provide the ability to safely place the polymer-based implant in an ocular region without undesired diffusion and also to allow for controlled and timely release of the therapeutic agent to a desired region of the ocular region, such as the retina. In particular disclosed embodiments, the polymer-based implant can be used for safe and effective gene therapy.

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and / or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

The invention relates to the technical field of image processing, in particular to a retinopathy recognition method, system and device based on artificial intelligence and a medium, and the method comprises the steps: taking the eye of a detected pregnant woman as a target object, setting a preset position, scanning in the depth direction, obtaining point fault information, carrying out three-dimensional reconstruction, and generating a second image. Generating a third image, performing correction processing, presetting a straight line in the corrected image, obtaining pixel values corresponding to the positions where the first pixel and the second pixel are located, and obtaining the thickness data of each layer; taking the thickness data as a pixel value; setting the value of each layer of pixel to be equal to the thickness data of the layer; generating a fourth image; and establishing an image database, adding a disease marker to the reference image, training the image estimation model by using the reference image added with the disease marker, and outputting a disease corresponding to the fourth image. The method improves the prediction efficiency and accuracy of the eye fundus image.

The present invention refers to a sgRNA molecule comprising a targeting domain for specifically targeting a SNP in the BEST1 coding region of a pathologic allele, wherein said targeting domain consists of a sequence selected from the group consisting of SEQ ID NO: 3-8, 41-44, 14-20, 50-52 and 54-55, or a sgRNA molecule combination of specifically defined first and second sgRNA molecules, wherein the first and the second sgRNA molecule each comprise a targeting domain for specifically targeting a SNP in the BEST1 gene coding or non-coding region of a pathologic allele. The present invention also refers to a nucleic acid comprising a sequence that encodes the sgRNA molecule or sgRNA molecule combination and to nucleic acid combinations. The present invention further relates to a recombinant adenovirus-associated virus (AAV) comprising the nucleic acids according to the present invention or recombinant AAV combinations. The sgRNA molecule, the nucleic acid, the recombinant AAV and combinations are useful tools for editing of the target domain in the bestrophin-1 (BEST1) gene to restore BEST1 channel function by e.g. CRISPR / Cas9)-based gene editing. The present invention further relates to the sgRNA molecule, the sgRNA molecule combination, the nucleic acid, the nucleic acid combination, the recombinant AAV and the recombinant AAV combination for use in a method for treatment of the human or animal body by surgery or therapy and for use in method of treating or preventing BEST1-related retinopathies, in particular autosomal dominant BEST1-related retinopathies.

The present disclosure relates to methods and systems for quantifying the vascular pattern using ocular imaging that shows vessel profiles for the detection, prevention, and treatment of diabetic retinopathy and other related ocular vascular diseases.

The invention relates to the technical field of medical image processing, and discloses a premature infant retinopathy diagnosis system based on an isotropic convolutional network, which comprises an image acquisition module, a segmentation module, a partition module, a staging module and a result generation module. The segmentation module is used for processing the retina image by adopting an equivariant convolutional network, and accurately segmenting an optic disc and a lesion area; the partitioning module divides a retina region according to an optic disc segmentation result; the staging module integrates the lesion segmentation result and the zoning result to output lesion staging; and the result generation module integrates all information to generate a comprehensive diagnosis report. According to the premature infant retinopathy diagnosis method and system, the image segmentation precision is improved through the equivariant convolutional network, and the automatic and high-accuracy comprehensive diagnosis of the premature infant retinopathy is realized by utilizing the cooperative work of the modules, so that the clinical diagnosis and treatment decision is effectively assisted.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

The invention relates to a marker and a kit for predicting or diagnosing retinopathy of a premature infant and application of the marker and the kit, and provides the marker for predicting or diagnosing the retinopathy of the premature infant, and the marker is hsacirc0005789. The marker can be detected through peripheral blood, so that the detection convenience is greatly improved, and the detection cost is reduced.

To provide a nucleic acid molecule, and the like for targeting CYP4 V2 gene.SOLUTION: There are provided in the present disclosure: a nucleic acid molecule (e.g., sgRNA or gRNA molecule) for targeting CYP4 V2 gene encoding cytochrome P450, family 4, subfamily V, polypeptide 2 protein; and a donor nucleic acid molecule specific for CYP4 V2 gene. Additionally, there are provided the uses thereof for targeting, disrupting human CYP4 V2 gene, and / or correcting mutations (e.g., c.802-8_810del17insGC mutation) and for treating Bietti's crystalline retinopathy (BCD).SELECTED DRAWING: None

This invention discloses an evaluation system and device for assessing the severity or progression of retinopathy of retinal disease (RP). The core of the evaluation system and device is the use of the RP degeneration index or the RPE / ELM residual index, which can quantify the degree of retinal degeneration and is used to assess the severity or progression of RP disease.

The invention provides an application of USP7 (ubiquitin-specific protease 7) as a target spot in preparation of drugs for treating vascular abnormal leakage diseases, and relates to the technical field of biomedicine, USP7 (ubiquitin-specific protease 7) as a deubiquitination enzyme not only regulates tumor, nerve and immune related diseases, but also is closely related to vascular endothelial cell functions. In the vascular homeostasis, the USP7 can maintain the integrity of a vascular barrier and inhibit pathological leakage by stabilizing endothelial connexin such as VE-cadherin and beta-catenin; under the inflammation or hypoxia condition, through deubiquitination of HIF-1alpha or NF-kappa B pathway components (such as I kappa B alpha), vascular endothelial cell activation can be promoted, VEGF signal-driven abnormal angiogenesis or release of inflammatory factors can be aggravated, and diabetic retinopathy, tumor vascular hyperplasia and sepsis-related vascular leakage can be participated. According to the application, verification experiments prove that USP7 has a certain protection effect on vascular permeability, and a treatment strategy is provided for vascular abnormal leakage diseases clinically.

The invention provides a retinopathy auxiliary diagnosis system, and the system comprises an image enhancement module which carries out the defogging enhancement processing of an inputted fundus image set, and outputs an enhanced image set; the target detection module positions the optic disc and the macular of each fundus image in the enhanced image set, and outputs a positioning result; the orientation screening module judges and screens qualified images according to a positioning result and a predefined orientation rule; the extraction backbone of the double-branch classification network extracts high-level features and middle-level features; the first classification branch outputs a global classification result based on the high-level features; the second classification branch outputs a local classification result based on the middle-level features; and the diagnosis unit receives the global classification result and the local classification result to generate an auxiliary diagnosis result. According to the system, a discrete series model is replaced by an integrated architecture, redundant calculation is eliminated through connection of image enhancement and target detection, and the problem of high risk of missed diagnosis is solved through orientation evaluation, global and local branch parallel processing and collaborative optimization.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The present application relates to the field of traditional Chinese medicine, in particular to a kind of traditional Chinese medicine composition for treating central serous chorioretinopathy and application thereof.The present application provides a kind of traditional Chinese medicine composition for treating central serous chorioretinopathy, compared with the prescription of Chunzai Decoction, the traditional Chinese medicine composition of the present application increases the efficacy of promoting blood circulation and removing blood stasis, soothing the liver and relieving depression, clearing the liver and improving eyesight, clearing heat and reducing phlegm on the basis of Chunzai Decoction warming yang, transforming qi, reducing water and removing dampness;Compared with using Chunzai Decoction alone, the curative effect of patients using the traditional Chinese medicine composition is more direct, from 2-3 weeks to 1 week, and the curative effect is accelerated.And the traditional Chinese medicine composition of the present application has been used for about 2 years, 2 / 3 of the 112 patients can see effect in 1 week, and no recurrence is found within 3 months.

A use of a mulberry extract in preparing a drug which treats and / or prevents retinopathy, the mulberry extract including an alkaloid having an amount by weight of 3% or more, and / or including a polysaccharide having an amount by weight not higher than 70%, and / or including a flavonoid having an amount by weight not higher than 10%, and / or including an amino acid having an amount by weight not higher than 50%, and / or other components. Preparation of the mulberry extract comprises: 1) preparing a crude extract of a moraceae plant; 2) performing separation on the crude extract by means of a cationic resin and / or an optional anionic resin, to obtain a resin effluent; optional step 3): performing alcohol precipitation treatment on the resin effluent of step 2), and collecting a supernatant; 4) performing concentration and / or drying treatment on the supernatant; and optionally, before performing alcohol precipitation treatment on the resin effluent of step 2), performing concentration and / or drying treatment. The mulberry extract has a significant effect on improving retinopathy.

The present application belongs to the field of biomedicine. Disclosed are an siRNA for inhibiting KRAS gene expression, and a modified form thereof and the use thereof. Provided in the present application is a double-stranded RNA molecule targeting KRAS, wherein the molecule can treat KRAS-associated diseases such as metastatic non-small cell lung cancer, metastatic pancreatic ductal adenocarcinoma, KRAS G12C+ non-small cell lung cancer, diabetic retinopathy, leukemia, cholangiocarcinoma, metastatic colorectal cancer, gastric cancer, advanced non-small cell lung cancer, stage-IV non-small cell lung cancer, gastric adenocarcinoma, sepsis, KRAS G12C-mutated advanced non-small cell lung cancer and gallbladder cancer.

An rAAV-delivered Fc-engineered VEGF receptor fusion protein or an anti-VEGF antibody is provided and applied to the treatment of angiogenesis-related fundus diseases, such as age-related macular degeneration, wet maculopathy, diabetic retinopathy and other diseases. Based on the aflibercept-expressing gene, the recombinant AAV delivery is used to achieve long-term stable expression of a target gene in the RPE layer by means of genetic modification and vector optimization, thereby delivering an optimized target gene sequence to fundus cells of a patient.

The invention discloses a diabetic retinopathy segmentation method based on multiple branches and visual Mangbar, and relates to the field of medical image processing. The problems that small target lesions are difficult to accurately segment, the model is complex, the modeling ability of global context information is insufficient and the like still exist in the aspect of diabetic retinopathy in the prior art are solved. The invention provides a diabetic retinopathy segmentation model, which takes a color eye fundus image as input data, extracts multi-scale information through a multi-branch-based multi-scale attention fusion module MSAF Block, and obtains effective context information by using MSMFB of different scales. And meanwhile, a joint weighted jump module is constructed through a shared attention jump connection module to effectively fuse multi-level features, and finally, a final segmentation result is output through a lightweight decoder. Through the model, efficient segmentation of four lesions can be realized. The method is also suitable for the field of diabetic retinopathy image processing.

The application relates to the technical field of diabetic retinal vasculopathy, in particular to RNA, a pharmaceutical composition, a conjugate and application. The nucleotide sequence of the RNA is shown in SEQ ID NO:1. The RNA can inhibit the proliferation, tube formation and migration capacity of retinal vascular endothelial cells, thereby playing a role in inhibiting diabetic retinal angiogenesis. The RNA can also inhibit the inflammatory response caused by diabetic retinal vasculopathy, and has the effect of treating diabetic retinal vasculopathy.

The invention discloses application of a mulberry extract in preparation of a medicine for treating and / or preventing retinopathy. The mulberry extract comprises alkaloid with the weight content being 3% or above, and / or polysaccharide with the weight content being not higher than 70%, and / or flavone with the weight content being not higher than 10%, and / or amino acid with the weight content being not higher than 50%, and / or other components. The preparation method of the mulberry extract comprises the following steps: 1) preparing a crude extract of moraceae plants; 2) separating the crude extract by cationic resin and / or optional anion resin to obtain resin effluent, optionally 3) performing alcohol precipitation treatment on the resin effluent in the step 2), and collecting supernate; (4) concentrating and / or drying the supernate; optionally, before alcohol precipitation treatment is carried out on the resin effluent in the step 2), concentration and / or drying treatment are / is carried out. The mulberry extract has a remarkable effect of improving retinopathy.

Disclosed are peptides that are useful as agonists of GPR56. Also disclosed are compositions comprising at least two synthetic or recombinant peptides, each of the peptides comprising a sequence selected from LLSSR, GYYCG, and NQGCKL, or a sequence that has a sequence identity of at least 60% thereto, wherein when a peptide comprises sequence a) or b) the peptide has a length of from 5-25 amino acids and wherein when a peptide comprises sequence c) the peptide has a length of from 6-26 amino acids. The compositions are useful for treating diseases or conditions such as vascular dysfunction, cardiovascular disease, impaired pancreatic -cell function, type II diabetes, impaired glucose tolerance, liver dysfunction, cirrhosis, liver cancer, depression, Alzheimer's disease, retinopathy and Attention deficit hyperactivity disorder.

The present invention relates to a composition for inhibiting angiogenesis containing yohimbine, and more specifically, to a pharmaceutical preparation and a functional food containing a composition capable of exhibiting preventive, improving, and therapeutic effects on angiogenesis-related diseases such as hemangioma, vascular adhesion, neovascular glaucoma, diabetic retinopathy, macular degeneration, corneal disease caused by neovascularization, or telangiectasia by containing yohimbine capable of inhibiting PDGF-induced vascular smooth muscle cell proliferation and migration through the factor FOXO3a.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.